Curr Opin Immunol. 2025 Jul 3;95:102605. doi: 10.1016/j.coi.2025.102605. Online ahead of print.
ABSTRACT
PURPOSE OF THE REVIEW: Platelet and red blood cell (RBC) transfusions, whether used as prophylactic measures or therapeutic interventions, are critical for saving lives. However, the composition of platelet and RBC concentrates used for transfusion may contribute to adverse reactions following transfusion.
RECENT FINDING: Recent studies on platelet and RBC concentrates have focused on their composition, including lipid mediators and proteins such as cytokines and chemokines, and their potential role in transfusion-related adverse reactions. This review aims to synthesize both recent and earlier findings, offering an overview of the involvement of these bioactive molecules in transfusion reactions.
SUMMARY: Lipid mediators and proteins could serve as predictive biomarkers for adverse reactions to specific transfusions. The integration of personalized medicine/transfusion should be explored to optimize transfusion practices and improve patient outcomes.
PMID:40614696 | DOI:10.1016/j.coi.2025.102605